Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sanofi-Aventis S.A. ADR (NQ: SNY ) 56.21 +0.98 (+1.77%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sanofi-Aventis S.A. ADR < Previous 1 2 3 4 5 6 7 8 9 ... 29 30 Next > Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy? August 24, 2024 Don't be too quick to jump on the Wall Street bandwagon. Via The Motley Fool ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst August 20, 2024 "FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and... Via Benzinga Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell? August 19, 2024 Its 12-month relative strength performance is impressive, but Novavax now faces resistance. Via Investor's Business Daily NASDAQ:SNY is probably undervalued for the fundamentals it is displaying. August 19, 2024 SANOFI-ADR (NASDAQ:SNY) appears to be flying under the radar despite its strong fundamentals. Via Chartmill Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk August 16, 2024 A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a broader scientific consensus that there is no consistent evidence supporting... Via Benzinga NASDAQ:SNY may be ready to breakout. August 12, 2024 Will SANOFI-ADR breakout? Via Chartmill 3 Biotech Stocks to Buy on the Dip: August 2024 August 15, 2024 These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning. Via InvestorPlace AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering August 14, 2024 The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis. Via Investor's Business Daily Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp? August 12, 2024 Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. Via MarketBeat Exposures COVID-19 FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment August 09, 2024 FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This new option offers a non-injection alternative to epinephrine autoinjectors,... Via Benzinga Exposures Product Safety BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model August 08, 2024 Via Investor Brand Network COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit August 08, 2024 Novavax reported Q2 2024 revenue of $415 million, missing estimates, with net income rising to $162 million. EPS increased to $0.99, below expectations. The company revised its 2024 revenue guidance to... Via Benzinga Exposures COVID-19 Sanofi's Approved Blood Cancer Drug Sarclisa Shows Improved Progression-Free Survival In Patients Eligible For Transplant August 08, 2024 Sanofi's phase 3 GMMG-HD7 study reveals that Sarclisa, combined with lenalidomide, bortezomib, and dexamethasone, significantly prolongs progression-free survival in newly diagnosed multiple myeloma... Via Benzinga Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities August 06, 2024 EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END Via FinancialNewsMedia Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities August 06, 2024 From FN Media Group LLC Via GlobeNewswire Where Will Novavax Be in 5 Years? August 03, 2024 Its been a good year so far for the biotech, but how long can it keep the momentum going? Via The Motley Fool Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs August 01, 2024 Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD, Dupixent, and Libtayo. Notable: 18% decline in Eylea US sales; 42%... Via Benzinga JPMorgan Just Cut Its Price Target on These 3 Stocks: July 31, 2024 July 31, 2024 Analysts from JPMorgan Chase have expressed their concern about the outlook for these stocks with lowered price targets. Via InvestorPlace JPMorgan Just Issued a Warning on Novavax (NVAX) Stock July 30, 2024 Novavax has inked a key vaccine deal with Sanofi, but NVAX stock is down after JPMorgan warned about overvaluation concerns. Via InvestorPlace Sanofi (SNY) Q2 2024 Earnings Call Transcript July 25, 2024 SNY earnings call for the period ending June 30, 2024. Via The Motley Fool Topics Earnings Exposures Financial Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand July 25, 2024 Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast. Via Benzinga 25 Best Artificial Intelligence Stocks to Buy Right Now July 25, 2024 Artificial intelligence is revolutionizing industries across the board. These 25 companies span the spectrum, providing investors with a diversified basket of AI-centric equities. Via The Motley Fool Topics Artificial Intelligence Exposures Artificial Intelligence Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday? July 25, 2024 Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last quarter, countering concerns of a slowdown. Via Benzinga Topics Economy Exposures Economy American Airlines, AstraZeneca And 3 Stocks To Watch Heading Into Thursday July 25, 2024 Via Benzinga AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife July 23, 2024 The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market. Via Benzinga Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House July 25, 2024 Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech... Via Benzinga Topics Government Stocks Exposures Political US Equities European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment July 17, 2024 European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. Via Benzinga Exposures COVID-19 Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally July 21, 2024 The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season. Via Benzinga Stable Blue-Chip Stocks to Buy Before Earnings Season July 17, 2024 Don't miss out on these stable blue-chip stocks to buy now. Explore their potential for steady returns and long-term portfolio growth. Via InvestorPlace Senate To Review Novo Nordisk's Levemir Insulin Discontinuation July 16, 2024 Novo Nordisk will meet with U.S. Senate aides to discuss the discontinuation of Levemir, its long-acting insulin, amid concerns about manufacturing constraints and patient access. Senators press for... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 29 30 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.